Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20974391 | 0.79 | CYP2D6 (0.43) | CYP2D6CYP2C19 | |
| SCHEMBL28722785 | 0.78 | CYP2D6 (0.56) | CYP2D6CYP2C19 | |
| SCHEMBL14842174 | 0.75 | PMP22 (0.30) | — | |
| SCHEMBL20480543 | 0.74 | HPGD (0.40) | CYP2D6CYP2C19 | |
| SCHEMBL354239 | 0.74 | CYP2D6 (0.50) | CYP2D6CYP2C19 | |
| SCHEMBL19210480 | 0.72 | CYP2D6 (0.48) | CYP2D6CYP2C19 | |
| SCHEMBL272596 | 0.71 | NPC1 (0.46) | — | |
| SCHEMBL14844664 | 0.70 | CYP2D6 (0.44) | CYP2D6CYP2C19 | |
| SCHEMBL8222868 | 0.70 | DPP4 (0.37) | CYP2D6CYP2C19 | |
| SCHEMBL19746069 | 0.69 | CYP2D6 (0.40) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544130-B2 | Metallo-beta-lactamase inhibitors | MLX, ZFX, MMP12 | CYP2D6 704/4885CYP2C19 394/4885 |
| US-20190144432-A1 | METALLO-BETA-LACTAMASE INHIBITORS | MLX, ZFX, MMP12 | CYP2D6 704/4885CYP2C19 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.